Q3 FY2025 Earnings April 23, 2025 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of Resmed Inc., its subsidiaries, and its legal entities for the periods indicated. Devices Masks & Other OOH RCS 12% 12% 36% 52% Revenue by business LTM 3Q25 This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well a ...

SAN DIEGO, April 23, 2025 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Exhibit 99.1 Third Quarter 2025 Highlights For investors For media +1 858-836-5000 +1 619-510-1281 investorrelations@resmed.com news@resmed.com All comparisons are to the prior year period "Our positive fiscal year 2025 performance continued in the third quarter, with strong top-line revenue growth, margin expansion, and double-digit EPS growth resulting from solid customer demand for ...

Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a cons ...

Core Insights - Resmed has appointed Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025, to lead its global investor relations function [1] - Schwartz brings over two decades of experience in finance roles within health tech and financial services, previously serving as Head of Investor Relations at Illumina [2] - The appointment is seen as critical for advancing Resmed's 2030 strategy aimed at enhancing shareholder value and improving health outcomes for 500 million people globally [3] Company Overview - Resmed is a leader in health technology focused on sleep, breathing, and home care, with a mission to empower individuals in 140 countries to achieve better health [4] - The company utilizes AI-powered digital health solutions and cloud-connected devices to personalize and enhance home healthcare [4]

Wall Street analysts forecast that ResMed (RMD) will report quarterly earnings of $2.36 per share in its upcoming release, pointing to a year-over-year increase of 10.8%. It is anticipated that revenues will amount to $1.28 billion, exhibiting an increase of 7.3% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estima ...

ResMed (RMD) shares rallied 3.8% in the last trading session to close at $213. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.7% loss over the past four weeks.ResMed scored a strong price increase, on investors’ optimism surrounding its impending fiscal 2025 third-quarter financial results, which is slated to release on April 23 after market close. In the last reported quarter, the company achieved robust ...

Company Overview - Resmed Inc. has launched its home sleep apnea test, NightOwl, across the United States, which is designed to provide a simplified and efficient way to diagnose obstructive sleep apnea (OSA) from home [1] - The company has a market capitalization of $31.33 billion and has delivered an average earnings beat of 6.86% over the trailing four quarters [4] Product Features - NightOwl is a disposable home sleep apnea test device that records up to 10 nights of sleep data, transmitting this data to a cloud-based platform for physician analysis [5] - The device utilizes peripheral arterial tonometry technology to measure changes in blood flow, oxygen saturation, and pulse rate to detect OSA [5] - Key features include autoscaling raw patient data with a clinically validated algorithm, integration with leading sleep lab management software, and pairing with the myAir app for user guidance [6] Market Context - The global sleep apnea device market was valued at $4.5 billion in 2023 and is projected to grow at a CAGR of 6.2% through 2030, driven by an aging population and increased focus on innovative product development [10] - OSA affects nearly 1 billion people globally, with approximately 80% of cases remaining undiagnosed, highlighting a significant market opportunity for Resmed's NightOwl [7] Strategic Initiatives - Resmed is ramping up demand-generation initiatives to raise awareness and create care pathways for patients suffering from sleep suffocation, positioning NightOwl as a pivotal step in its strategy [3] - The company recently unveiled a comprehensive brand evolution to unify its brands under a single health technology brand, aiming to enhance direct-to-consumer engagement [11] Stock Performance - Following the NightOwl announcement, shares of Resmed grew marginally by 0.3% in after-market trading, with a 15.4% increase in shares over the past year compared to the industry’s 11.3% growth [2]

Core Insights - Resmed has launched its FDA-cleared home sleep apnea test, NightOwl™, across the United States, aimed at simplifying the diagnosis of obstructive sleep apnea (OSA) for healthcare providers and patients [1][5]. Company Overview - Resmed is a leading health technology company focused on sleep, breathing, and home care, committed to innovative technology that empowers individuals to live healthier lives [5]. - The company envisions a world where everyone can achieve their full potential through better sleep and breathing, with care delivered at home [5]. Product Features - NightOwl is a disposable home sleep apnea test device that records up to 10 nights of sleep data, capturing variability and providing clinicians with a comprehensive view of sleep patterns [3][7]. - The device uses peripheral arterial tonometry technology to measure blood flow changes, oxygen saturation, and pulse rate, demonstrating high accuracy in detecting OSA [4][7]. - NightOwl integrates with Resmed's myAir™ app, offering step-by-step guidance for users throughout the testing process [7]. Market Context - OSA affects nearly one billion people globally, with approximately 80% of cases remaining undiagnosed and untreated, highlighting the need for accessible diagnostic options [2]. - A study indicates that treating OSA with CPAP therapy can significantly reduce the risk of death, emphasizing the importance of effective diagnosis [2][3].

Core Viewpoint - Resmed plans to release its financial and operational results for Q3 of fiscal year 2025 on April 23, 2025, after market close, followed by a management webcast to discuss the results and other relevant information [1] Company Overview - Resmed is dedicated to creating innovative health technologies that enhance the quality of life for individuals, with a commitment to pioneering AI-powered digital health solutions and cloud-connected devices [2] - The company aims to empower millions across 140 countries to achieve better health outcomes through personalized home healthcare solutions [2] Earnings Webcast Details - The earnings webcast will take place on April 23, 2025, at 1:30 p.m. PDT / 4:30 p.m. EDT, with international times provided for London and Sydney [3] - A replay of the webcast will be available on Resmed's website approximately two hours after the live event, with a phone replay accessible from April 23, 2025, until May 7, 2025 [2][3]

Core Insights - A landmark meta-analysis published in The Lancet Respiratory Medicine indicates that CPAP therapy significantly reduces mortality risks for individuals with obstructive sleep apnea (OSA), showing a 37% lower risk of all-cause death and a 55% lower risk of cardiovascular-related death [1][2][8] Company Overview - Resmed, a leader in health technology focused on sleep and breathing, announced the publication of this meta-analysis, which analyzed data from over 1 million OSA patients globally, providing strong evidence that CPAP therapy not only alleviates symptoms but also prolongs life [2][3] - The company emphasizes the importance of consistent CPAP use, as untreated OSA is a major modifiable risk factor for mortality [3][4] Industry Context - OSA affects over one billion people worldwide, with more than 80% of cases undiagnosed and untreated, leading to serious health conditions such as hypertension, diabetes, and cardiovascular disease [3][4] - The study reinforces CPAP therapy as the gold standard for OSA treatment, highlighting its effectiveness without the need for drugs or invasive procedures [3][4] Research Findings - The meta-analysis is the largest of its kind, pooling data from 30 studies, including 10 randomized controlled trials and 20 real-world evidence studies, with an average follow-up period of nearly five years [4][5] - A dose-response relationship was identified, indicating that increased consistency in CPAP use correlates with greater survival benefits for OSA patients [8]